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ABSTRACT
DREADD Targeting Projections from the Nucleus Accumbens to the Ventral Pallidum with
Nicotine Self-Administration
by
Amanda L. Smith

Projections from the Nucleus Accumbens (NAc) to the Ventral Pallidum (VP) play a critical role
in motivation and reward. Rewards and reward-associated cues are thought to alter this pathway
by suppressing GABA release to the VP, however, the role of the NAc to VP pathway has never
been investigated with regard to nicotine self-administration. We hypothesized that increasing
GABAergic signaling from the NAc to the VP would decrease the reinforcing effects of nicotine.
To increase GABA release, CRE dependent DREADD was expressed in the NAc of male rats.
Administration of low dose clozapine activated the DREADD receptor and showed a reduction
in responding for nicotine suggesting that activation of the NAc to VP pathway reduced
reinforcement. However, a nonspecific effect was observed leading to future investigation of
locomotor activity. Immunohistochemistry and microdialysis were used to confirm DREADD
expression in the NAc and increased extracellular GABA in the VP.
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CHAPTER 1
LITERATURE REVIEW
Project Overview
Substance dependence is widely considered to be a ‘brain disease’ – or, more specifically
a disorder of maladaptive neuroplasticity (Nestler 2014). External stimuli, cognition, behavior,
and emotion can remap the brain to alter its responses to future circumstances (Fuchs and Flügge
2014). Drugs of abuse can directly alter neuroplasticity in circuits that mediate motivation and
approach behaviors, distorting the reward and reinforcement derived from the addictive drug and
its associated stimuli (Lüscher and Malenka 2011). These synaptic changes in brain circuits can
lead to craving, unsuccessful quit attempts, and taking the drug in increasing amounts.
Dependence (used interchangeably with ‘addiction’) is traditionally defined as ‘loss of control’
over drug taking - most addicts will continue to use a substance despite persistent problems
related to taking the drug (American Psychiatric Association 2014). A common example is a
chronic smoker continuing to smoke tobacco cigarettes after the diagnoses of a chronic
respiratory disease, like emphysema. Even with negative consequences, motivation to seek and
consume the drug still persists. Drugs of abuse are portrayed to ‘hijack’ the brains reward system
promoting changes that lead to impair judgement, memory, and decision making (Pfaus and
Blaustein 2015; National Institute of Drug Abuse 2018). A large amount of funding and research
been invested into understanding why humans continue to desire a drug. Clinical trials use
imaging, like fMRI or functional magnetic resonance imaging, to show what areas of the brain
are activated during cravings, reward, or withdrawal. However, it is not plausible to use a human
model when converging the neurobiology behind the behavior. The best alternative option is
using an animal model which allows for more diverse methods when investigating dependence.
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Animal Model
Animal models of substance dependence have provided more perspective about the
complex neurobiology of this disorder. Conditioned place preference, intracranial selfstimulation, and drug self-administration are a few of the developed models that have allowed
researchers to observe behavior and further understand the function of reward and motivation in
non-human animals (Feltenstein and See 2008). Rodents Rats have the ability to perform
multifaceted cognitive tasks which allow for highly translational data and invasive manipulations
(Iannaccone and Jacob 2009). Not only has rodent behavioral testing shown relevance to clinical
studies but has also provided validity of the similarities in neurochemical and neuroanatomy
involved in drug-associated behaviors between rodents and humans. Rodents will not only
voluntarily self-administer the same abusive drugs but will do so in comparable ways including
intravenous and orally self-administration (Spanagel 2017). The animal model is an excellent
way to further understand the changes in the reward pathway associated to drug use specifically
the more common consumed drug, nicotine.
Nicotine
Nicotine is a readily available psychostimulant found in tobacco cigarettes, smokeless
tobacco, and vaping products. In the United States, smoking tobacco cigarettes is one of the
leading causes of smoking-related premature deaths including cancer, cardiovascular disease,
and pulmonary diseases. An estimated 45 million Americans smoke with only 3% successfully
quitting (Benowitz 2010). Heath risks of smoking or the use of smokeless tobacco are well
known and yet many still persist. Evidence has shown that nicotine alters the brains natural
reward system leading to dependence (Tomkins and Sellers 2001). The reward system is referred
to as the mesolimbic dopaminergic system and is a common target among all drugs of abuse
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(Lüscher and Malenka 2011). Nicotine controls the mesolimbic system by binding to 42
nicotinic acetylcholine receptors expressed on dopaminergic neurons increasing pleasure and
mood (Benowitz 2010). The psychostimulant effects of nicotine may not be comparable to
cocaine or other drugs of abuse. It does, however, activate the same dopaminergic pathways
making nicotine a reliable drug when investigating dependence.
Reward Center
Perhaps the most commonly studied target of substance dependence is the
mesocorticolimbic dopamine system, which mediates incentive motivation and approach
behaviors evoked by natural rewards (e.g., sex, food, and social interactions; Feltenstein and See
2008). The mesocorticolimbic system is constructed from two overlapping circuities called the
mesolimbic and mesocortical dopaminergic systems that stem from dopaminergic neurons within
the ventral tegmentum area (VTA) in the midbrain which sends projections to various forebrain
structures (Chinta and Andersen 2005). The mesolimbic system is comprised of reciprocal
projections from the VTA to the nucleus accumbens (NAc), amygdala, hippocampus, olfactory
tubercle. While projections from the VTA to the prefrontal, cingulate and perirhinal cortices
comprise the mesocortical system (Chinta and Andersen 2005), the dopaminergic projection
from the VTA to the NAc is commonly referred to as the ‘final common pathway’ of dependence
because inhibition of dopamine (DA) release or blockade of DA receptors in the NAc reduces or
abolishes the reinforcing effects of drugs, drug-associated cues, and relapse-like behavior evoked
by drug-associated cues (Feltenstein and See 2008). Increased DA in the NAc has been
implicated in associative learning, incentive salience, reward prediction, and memory (Kelley
and Berridge 2002). The NAc is also a point of convergence in the mesolimbic pathway; in
addition to the dopaminergic projections from the VTA, the NAc receives glutamatergic
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afferents from the prefrontal cortex (PFC) and hippocampus, which presumably also alter
neuroplasticity in response to drugs of abuse (Lüscher and Malenka 2011).
Indirect and Direct Pathways
The NAc is located ventrally in the corpus striatum of the basal ganglia and is comprised
of two parts: the core and shell (Dafney and Rosenfeld 2017). While DA is one of the main
neurotransmitters released in the NAc, glutamate and GABA are also thought to help regulate
goal-directed behaviors through integration of the limbic system (Dafney and Rosenfeld 2017).
The neuronal structure of the ventral striatum is predominantly medium spiny neurons (MSNs)
that synthesize the inhibitory neurotransmitter, GABA (Perreault et al. 2011). MSNs are
subcategorized by their expression of dopamine D1 and D2-like G protein-coupled receptors and
corresponding involvement in the indirect and direct pathways, although some overlapping exists
(Lobo and Nestler 2011). These two distinct pathways have been identified and used in
understanding integration of reward and drug-seeking behaviors.
The striatopallidal “indirect” pathway consists of MSNs that predominantly express
dopamine D2-like receptors and project from the striatum to the external globus pallidus (GP)
(Perreault et al. 2011). The second striatonigral “direct” pathway is known for dopamine D1-like
receptor expression and projections to substantia nigra reticulata and internal segment of the GP
(Perreault et al. 2011). The direct and indirect pathways are thought to combine to control
thalamic output – with the indirect pathway serving as a ‘brake’ on the direct pathway (Perreault
et al. 2011). DA is believed to have opposing effects on dopamine D1 and D2-like receptors
within these two pathways (Gallo et al. 2018). Recent evidence has suggested that dopamine D1like receptors are low affinity (e.g., activated primarily by large increases in DA release) and
activated in response to delivery of rewards and anticipation of rewards. In contrast, DA D2-like
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receptors are low affinity (activated by small increases in DA tone) and appear to be associated
with drug seeking mechanisms (Lobo and Nestler 2011). While addiction research of the NAc
has allowed for insight into the mechanism of drug-associated reward and reinforcement, its
efferents to thalamocortical circuits and their contributions to regulation of reward and approach
behavior have been under-studied in the substance dependence literature (Smith et al. 2009).
Innervation of Indirect Pathway onto the VP
The ventral pallidum (VP) receives the primary GABA-ergic efferent from the NAc
MSNs in the indirect pathway (Gallo et al. 2018). The VP was once considered part of the GP,
but has more recently been identified as its own brain region (Smith et al. 2009). GABAergic
neurons are the primary neuronal component of the VP and are associated with inputs of GABA
and non-GABA transmission from the striatum (Root et al. 2015). Because of the location and
reciprocating projections from various brain regions, it is hypothesized that the VP plays a
crucial role in motor output for limbic motivation signals (Smith et al. 2009). The MSNs of the
NAc project primarily to the VP which allows for incorporation of the direct and indirect
pathways through D1 and D2-like receptor activity (Creed et al. 2016). A focus has been placed
on the innervation of the MSNs expressing D2-like receptors and the VP. Activation of these D2like receptors are thought to reduce inhibitory transmission to the VP enhancing the motivation
or willingness to work for a rewarding external stimuli (Gallo et al. 2018). Modifications to the
indirect pathway could theoretically alter the incentive motivation for the reward. These types
manipulations can be accomplished using a chemogenetic technique called DREADD.
Neuronal Manipulation
Chemogenetics is becoming a more valued method when attempting to understand
neuronal signal transduction. It can manipulate cells via alterations to proteins, G protein-
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coupled receptors, or ligand-gated ion channels (Roth 2016). Designer Receptors Exclusively
Activated by Designer Drugs, or DREADD, is a form of a chemogenetic technique gaining
acclamation because of its ability to distort neuronal transmission using a mutated G proteincoupled receptor (GPCR) that only responds to a synthetically designed ligand. The design for
the DREADD receptor evolved from the human seven-transmembrane domain muscarinic
receptor. The developed receptor was mutated to specifically respond to clozapine-n-oxide
(CNO) and metabolites but not to the endogenous ligand, acetylcholine (Zhu and Roth 2014).
Recent evidence has shown that CNO metabolizes back into clozapine showing conflicting
results of both CNO and clozapine activating DREADD receptors (Gomez et al. 2017) (Zhu and
Roth 2014). Three DREADD signaling pathways have been produced and behave in different
ways: hM3Dq induces neuronal transmission, hM4Di inhibits neuronal transmission, and rM3Ds
which modulates neuronal activity (Zhu and Roth 2014). DREADD expression has shown to be
high in injected brain regions because of the cell-type promoter associated with the DREADD
genome and is tagged with a florescent protein. This also means that expression is not specific
(Roth 2016). To increase specificity, a Cre-recombinase dependent DREADD was produced.
Cre-recombinase is an enzyme that recognizes specific regions within the DREADD
genome. Expression of Cre-recombinase can be implicated through animal genetic modification
and breeding or through viral administration discussed in detail below. DREADD expression
became more selective with the production of a modified double-floxed open reading frame in an
antisense configuration (Smith et al. 2016). Located on both sides of the reading frame are LoxP
sites which are recognized by Cre-recombinase. Cre-recombinase cuts and flips the inverted gene
transforming the reading frame into a sense configuration and allowing for DREADD expression
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(Smith et al. 2016). This method increases selective targeting by restricting DREADD expression
in neurons that do not already express Cre-recombinase.
As previously mentioned the genes responsible for Cre-recombinase and DREADD
expression can be administered through viral applications. The common virus used is the Adeno
Associated-Virus (AAV). AAV is not autonomously replicating unless the assistance from a
helper virus occurs. While a virus may seem dangerous, to administer to animals or humans,
researchers have constructed different AAVs to have little or no immune response (Mingozzi and
High 2013). AAVs can infect cells through normal endocytosis or retrograde activity making
them perfect for neuronal targeting. The Roth lab has combined the AAV and DREADD
allowing for a molecular manipulation of neuronal transmission (Roth 2016).
In this study, Cre-dependent DREADD was used to manipulate and further understand
the motivational pathway of the brain with nicotine. Currently addiction treatment consists of
medication that mimics abusive drugs, behavioral counseling, treating withdrawal, and long-term
follow up appointments (NIDA 2018). The brain is complex and is not fully understood. With
that being said, this research combined with the studies previously mentioned could provide a
more clear understanding about neuronal pathways associated with motivation and habitual drug
use. Therefore providing new therapeutic opportunities and further insight into substance abuse
disorder.
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CHAPTER 2
DREADD Targeting Projections from the Nucleus Accumbens to the Ventral Pallidum with
Nicotine Self-Administration
Introduction
The nucleus accumbens (NAc) has been a major target in understanding the intricacy of
drug dependence. Various research has shown the effects of commonly abused drugs on
dopamine levels and receptors expressed on neurons within the NAc. With an increasing amount
of data implicating the importance of the NAc to the reward of a drug, a new interest in incentive
motivation has immerged. This has shifted the focus to the ventral pallidum (VP) and its role in
drug incentive motor integration.
The NAc primarily consists of GABA transmitting medium spiny neurons (MSN)
expressing D1-like and D2-like dopamine receptors. Cells that express D1-like receptors are part
of the direct pathway – the receptors have lower affinity for dopamine (e.g., require more
dopamine release before they are activated), therefore, stimulation of these receptors increases
reward-based motivation and approach to incentive stimuli (Day and Carelli 2007). In contrast,
D2-like receptors are high affinity (e.g., require less dopamine release to be activated) and are
part of the ‘indirect pathway’ which regulates reward-based motivation and reduces approach to
incentive stimuli (Hamada et al. 2004). Unlike D1 receptors which activate the direct pathway,
D2-like receptors inhibit the indirect pathway. Inhibition would decrease the incentive
motivational inhibitor and may have different effects on behavior. This would inhibit the indirect
pathway and reduce inhibition on incentive behaviors, causing an increase in unfocused search
behaviors. The indirect pathway includes projections from the NAc to the Ventral Pallidum
(VP). Stimulation of NAc D2-like receptors decrease GABA release in the VP, which leads to a
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‘release from inhibition’ on incentive motivation (Smith et al. 2009). All drugs of abuse activate
the incentive motivational systems of the brain and either increase DA release in the NAc or
mimic the effects of increased DA release in the NAc (Lüscher and Malenka 2011).
The effects of nicotine on the direct and indirect pathway are currently unclear. For
example, naïve rats exposed to nicotine injections showed approximately 100% increase in
extracellular DA in the NAc (Rada et al. 2001), but this increase pales in comparison to other
drugs of abuse such as cocaine, which can cause over 500% increases in extracellular DA
(Andrews and Lucki 2001). Theoretically, nicotine induced DA release activates the indirect
pathway implying that after brief activation by nicotine, a tobacco user’s incentive system might
be released from inhibition – making them more sensitive to non-drug rewards because the
indirect pathway has essentially been tuned-down. Such effects could make the act of smoking,
the smoking-associated stimuli (flavors, smells, actions associated with smoking) and
social/contextual cues (friends, alcohol drinking, bars, parties, etc.) more salient incentives and
more likely to increase behavior in the future. Therefore, if the indirect pathway could be
activated, a reduction in nicotine self-administration should be observed.
To alter the indirect pathway, Designer Receptors Exclusively Activated by Designer
Drugs, or DREADDs, was used to selectively target neurons projecting from the NAc to the VP
pathways and control cellular function. DREADD is a single DNA strand containing the makeup
for a designer G-coupled muscarinic receptor that, in this study, is dependent on CreRecombinase (CRE) for expression (Kwon and Schaffer 2008). CRE, like DREADD, is not
endogenous to neurons and must be implanted using an adeno-associated virus (AAV) that
induces retrograde expression of CRE into the VP. All neurons with projections to the VP should
be targeted and express CRE. The synapsin 1 promoter ensured that selectivity occurred of
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targeted neurons and not glial cells (Madisen et al. 2015). After 2-3 weeks, CRE-dependent
DREADD was injected into the NAc. By doing so, only neurons that project from the NAc to the
VP should express the DREADD. Once the DREADD is expressed it can be activated by a low
dose of clozapine, which was too low to bind to dopamine receptors (Gomez et al. 2017). The
DREADD used changed the neuronal function by causing increased transmission. In this study,
the DREADD was predicted to increase GABA release from the MSNs in the NAc to the VP,
with the goal of increasing activity in the indirect pathway and reducing nicotine selfadministration.
Hypotheses
1. Activation of DREADD in the NAc will cause an increased GABA concentration in the
VP.
2. The administration of clozapine will not affect nicotine self-administration of control
animals.
3. Increased GABA release to the VP via activation of the indirect pathway will cause a
reduction in nicotine self-administration.
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Materials and Methods
Subjects
Adult male Sprague Dawley rats (Charles River) were used for the experiment. Rats were
individually housed and on a 12:12 hour light and dark cycle. All experiments took place during
the dark cycle. Upon arrival, each rat had unrestricted access to food and water until weight
exceeded 200 g. Food was then restricted to 15-20 g daily with unrestricted water for the
remainder of the study.
Apparatus
Conditioning Chambers
Self-administration occurred in ten Med-Associates (Georgia, VT) operant chambers
(ENV-008CT) measuring 30.5 × 25.4 × 30.5 (w × l × h). Each chamber individually housed a rat
in a ventilated, sound and light attenuated enclosure. A receptacle containing a liquid dipper was
located on the right side of the chamber. The dipper had a 0.1 ml cup attached to a motorized
arm that delivered a sucrose reinforcer. The sucrose reinforcer was only used during training.
Two retractable levers (ENV-112CM) were located on each side of the receptacle, 12 cm above
the grid flooring. Pressing the active lever, left lever, earned a reinforcer. While pressing the
inactive lever, right lever, resulted in no reinforcer earned. All lever presses were recorded. A
stimulus light was located above each lever that would turn on when lever was pressed and
retracted. During conditioning a house light located at the top of both sides of the chamber,
approximately 28.5 cm above the floor, remained on until reinforcer was earned. House light
would then turn off for a 30 second time out. Each operant conditioning chamber was equipped
with a drug delivery system with a syringe pump (Med-Associates, model PHM100 – 10rpm)
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that would deliver intravenous drug throughout all experiments. Recorded data collection from
the operant chambers took place on a computer using MED-PC V software programming.
Drugs and Solutions
Intraperitoneal Solution
Clozapine (Cayman Chemical) was dissolved into 1 ml of 1M HCl. NaOH was used to
pH the solution to 7.0 (±2). The clozapine concentrations were tested between 0.03 - 0.75 mg/kg
to find the most affective dose. Clozapine was administered into the peritoneal cavity (ip) 30
minutes prior to the animal being placed into the operant chamber.
Intravenous Solution
Nicotine hydrogen tartrate salt (Stigma, St. Louis, MO) was diluted with 0.9% sterile
saline to form a 30 g/kg concentration. NaOH was used to pH solution to 7.0 (±2). Nicotine
was self-administered through the animal’s intrajugular catheter. The volume self-administered
by the rat was weight dependent. For a control solution, 0.9% sterile saline was used.
Surgery
Surgery 1: Intravenous Catheter and Retro AAV Placement
Intravenous Catheter. Each catheter was constructed using a blunt 22 gauge needle bent
to form a 90o angle that was attached to a silastic tube (Dow Corning, Michigan) (0.51 ID x 0.94
mm OD) 175 mm in length. To secure the tubing to the needle, a nylon washer (.09 x .25 x .062)
(Fastenal, Minnesota) positioned on both sides of a round patch of polyester fabric (37.5 mm
diameter) was placed at the base of the needle and fastened by medical device epoxy adhesive
(LOCTITE EA M-21 HP, Henkel, North Carolina). Lastly, a silicone ball (3 mm diameter) was
attached 40 mm from end of tubing using 100% RTV silicone (DAP, Maryland). All surgical
equipment and catheters were sterilized by an autoclave treatment prior to surgery. Each rat was
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placed under an inhaled anesthetic, Isoflurane USP (Henry Schein) and equipped with a chronic
jugular vein catheter. The catheter exited between the two scapulae while the tubing was placed
under the right front extremity. The tubing was then positioned into the right jugular (IV) and
secured using two sutures. All incisions were closed using tissue staples. Ketoprofen (0.3mg/kg)
was administered subcutaneously on day 0 and followed two days after surgery. Timentin
(Ticarcillin and Clavulanate) diluted in heparinized saline was administered IV daily to prevent
infection and platelet clot formation. The animals were allowed one week for recovery before
nicotine self-administration began. Patency was checked consistently by injecting 0.2 mL
PropoFlo (200mg/20mL) IV.
Retro AAV. After catheter placement, each animal was placed in a stereotaxic apparatus
and remained under Isoflurane. An estimated one inch incision was made exposing the rat’s
skull. Bregma was measured and noted. The first bilateral intracranial injections targeted the
rostro medial VP (1.6 AP, 1.8 ML, -7.9 DV) at a 10 degree angle. The second bilateral
intracranial injection targeted the caudal lateral VP (-0.5 AP, 2.6 ML, -8.2 DV). The viral
infusion rate was set to 0.1L/min with a total infusion of 0.5L for each injection. Incision was
closed using tissue staples. Two weeks were given to allow for retrograde activity of the AAV
and viral genomic expression of CRE-Recombinase.
Surgery 2: AAV DREADD and Control Vector Placement
DREADD or Control. Each animal was anesthetized using Isoflurane and placed in a
stereotaxic apparatus. Incision and closing were the same as previously demonstrated. The
animals were divided into three groups: DREADD Nicotine, DREADD Saline, Control Nicotine.
Both DREADD Nicotine and DREADD Saline groups were injected with AAV expressing CRE
dependent DREADD into the NAc through bilateral intracranial injections (1.6 AP, 1.3 ML, -
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7.3 DV). The Control Nicotine group received the control AAV into the NAc with the same
coordinates stated above. For all intracranial injections into the NAc, the viral infusion rate was
set to 0.1L/min with a total infusion of 1.0L for each injection.
Procedures
Experiment 1
Training. Prior to any surgery, rats were trained to lever press for a reinforcer of sucrose
access through the receptacle. To begin, the left lever was inserted into the operant chamber for
15 s followed by activation of the liquid dipper allowing 0.1 ml sucrose access for 0.5 s. If the
lever was pressed during presentation, responses were recorded and the animal was given two
sucrose reinforcers separated by 5 s. The animal needed to earn 60 reinforcers within a 1-h
session to be considered successfully trained.
Intravenous Nicotine or Saline Self-Administration. After IV catheter implantation and
viral expression, rats were individually placed into the operant chambers and connected to the
syringe pump containing nicotine 30 g/kg or 0.9% sterile saline. Once the session began, both
retractable levers presented and operated on a fixed ratio (FR) for 1 h. Self-administration began
on a FR2 and increased to ten over a period of sessions. An increase in the FR was dependent on
data consistency. Once animals reached a FR10, Clozapine was administered chronically until
data collection was complete.
Microdialysis
Experiment 2
Microdialysis Surgery. Male Sprague Dawley rats (5n) that were placed under Isoflurane
and stereotaxically implanted ipsilaterally with the Retro AAV containing CRE-Recombinase
into the rostro medial VP (1.6 AP, 1.8 ML, -7.9 DV) at a 10 degree angle. Retro AAV was
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allowed two weeks for expression. Rats were then ipsilaterally implanted with the AAV
containing DREADD into the NAc (1.6 AP, 1.3 ML, -7.3 DV). Both viral infusions were
0.1L/min with a total infusion of 1.0L for each injection. An 18 gauge, cut 11 mm below
pedestal canula (PlasticsOne, Roanoke, VA.) was placed, on the same side as previous injections,
into rostro medial VP (1.6 AP, 1.8 ML, -6.7 DV) at a 10 degree angle. Dummy stylets were
placed into the cannula following surgery and reminded until the microdialysis collection
session. Animals were allowed one week to recover. During recovery rats were placed into
microdialysis chambers (Dr. Gerald Deehan PhD., East Tennessee State University) for a three
day habituation. A loop style microdialysis probe was inserted 2 mm below cannula into the VP
one day prior to microdialysis data collection.
Microdialysis Collection Assembly
Gamma-Aminobutyric Acid, GABA, dialysate was collected by connecting the
microdialysis probe directly to a microdialysis collection assembly. The assembly was
constructed with two pieces of tubing. One side connected to a swivel that perfused aCSF
towards the probe in the rat’s brain. This side was constructed 29 cm of PE20 tubing. The other
side collected aCSF coming from the microdialysis probe and was constructed of 29 cm of PE10
tubing with a ball 3 cm from the end. The plastic ball secured an amber vial and cap to the line.
GABA Data Collection
One day following probe placement, the rats were placed into microdialysis chambers
and connected to the collection assemblies. For the first 90 minutes one washout sample was
collected. This helped eliminate any potential contaminates. After the first 90 minute sample,
each sample was collected at 20 minute intervals. Baseline activity of GABA was collected over
a period of 100 minutes. Immediately after the fifth sample was collected, 0.75 mg/kg Clozapine
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was administered through intraperitoneal (IP) injections to each animal. Following the injection,
five more samples were collected. Clozapine was injected IP at 1.50 mg/kg succeeding collecting
ten more samples. This resulted in 400 minutes of total data collection. All samples were stored
in a -80o. GABA dialysate was analyzed through electrochemical detection via graphite electrode
using a EiCOM HTEC-510 HPLC machine (San Diego, CA). EiCOM AS-700 autosampler (San
Diego, CA) controlled by the Envision software detected and quantified GABA dialysate
samples using a one-sample t test.
Microdialysis Solution
Artificial Cerebrospinal Fluid. Artificial cerebrospinal fluid (aCSF) microdialysis
perfusion medium was composed of 145.0 NaCl, 2.7 KCl, 1.0 MgCl2, 2.5 CaCl2, and 2.0
Na2HPO4. aCSF was filtered through a sterile filter (pore size, 0.2 μM), and prepared the day of
microdialysis sessions. When necessary, the pH was adjusted to 7.4 with 0.1 N acetic acid. aCSF
was perfused through 2 mm loop-style probes at a rate of 1.0 μl/min.
GABA Mobile Phase. GABA mobile phase used for GABA dialysate analysis via HPLC
was composed of first dissolving 10.76 g NaH2PO4(2H2O), 3.95 g Na2HPO4(12H2O) in 800 mL
of HPLC grade water with an end pH of 6.0. Next 50 mL of methanol was added with 130 mL
acetonitrile, 5 mg EDTA(2Na). Solution was mixed until all particulate matter was dissolved.
GABA Standard. GABA/Glutamate standards were constructed for HPLC calibration and
controlled GABA and Glutamate detection. Standards were composed of -Aminobutyric acid
and L-Glutamic acid (Sigma) and diluted to a concentration of 100 nM GABA and 10 M
Glutamate using aCSF.
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Tissue Collection and Storage
Experiment 1
Perfusion. Concluding behavioral testing, animals were sacrificed by an overdose of
Isoflurane. During anesthesia, the animal was placed on its back and the thoracic cavity was
opened to fully expose the heart. A 30 gauge needle with tubing connected to a pump was
inserted into the left ventricle. A small laceration to the right atrium was placed to allow for
blood to flow out of the circulatory system. The descending abdominal aorta is clamped to
increase preservation of superior tissues. Once the needle had been placed, phosphate buffered
saline (PBS) 1x was perfused throughout the tissue for 20 min followed by 4%
paraformaldehyde. Once the blood had cleared from exposed tissues, the brain was then
extracted.
Tissue Fixation. The brains were placed in 4% paraformaldehyde in 4o for 24 h. The
tissue was then transferred into PBS 1x and stored in 4o for a minimum of 24 h. To cryoprotect
the tissue, brains were put in 30% sucrose and stored in 4o until tissue descended fully into
solution. Next, each brain was rinsed in O.T.C compound (Fisherbrand) and placed in a new
O.T.C for freezing. Brains were stored in a -80o.
Experiment 2
Directly after microdialysis, animals were sacrificed and tissue was preserved using the
same perfusion procedure and tissue fixation as defined above. However prior to tissue
extraction, Bromophenol blue (1%; 0.5μl) was perfused through the microdialysis probe to stain
the VP to confirm correct probe placement. The tissue then underwent the same histology as
experiment 1 described below.
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Histology
Tissue Slicing
The fixed brain tissue was cryopreserved and coronally sliced at 20 m. The slices were
immediately placed on colorfrost plus microscope slides (Fisherbrand) and stored at -20o.
Tissue Staining
Slides were kept in microscope slide box to reduce light exposure and allowed 30 min to
dry at room temperature prior to staining. Tissue borders were defined using a hydrophobic pen
and allowed to dry. The tissue was covered with a blocking solution containing PBS 1x, 2%
bovine serum albumin, and 0.3% Triton x100 was added to the tissue for 1 hr at room
temperature to increase tissue permeability. The blocking solution was then removed. Next the
primary antibody, rabbit anti-mCherry antibody from Abcam, was diluted to 1:800 with the
blocking solution defined above and added to fully cover sliced tissue. The primary antibody was
incubated overnight at 4o Celsius.
The following day, slides were washed (3 x 5 min) with a solution that contained PBS 1x
with 3% Triton x100 (PBS-T). The secondary antibody, Alex 594 donkey anti-rabbit IgG from
Jackson ImmunoResearch, diluted to 1:1000 in PBS-T was added to the tissue for a 2 h
incubation at room temperature. Slides were then washed (2 x 15 min) with PBS-T. A third wash
of PBS 1x for 15 min completed the staining process. The PBS 1x was removed and a
fluorescence mounting medium, Fluro-Gel (Electron Microscopy Sciences) was added followed
by a coverslip. After slides had dried overnight, a clear fingernail polish was applied to the
corners to secure the coverslips. Slides were stored at 4o Celsius in the dark until imaging.
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Fluorescence Imaging
Tissue was viewed using an Olympus BX41 microscope (Olympus America, Inc.) at a
wavelength of 594 nm (Dr. Donald Hoover, East Tennessee State University Biomedical
Sciences). Imaging was used to confirm bilateral DREADD expression in the NAc.
Statistical Analysis
Experiment 1: Nicotine Self-Administration
To investigate the effect of Virus (Cre vs. DREADD) and Drug (nicotine vs. saline) on
operant responding we conducted a 4-way mixed factors ANOVA with Virus and Drug as
between groups factors and Lever (Active vs. Inactive) as within subjects factor. For acquisition
Schedule (FR1, FR2, FR5, FR10) was a repeated measure. For clozapine challenge and saline
recovery tests, Test (day of treatment) was the repeated measure. Because not all levels of Virus
and Drug were represented in our design (e.g., no Cre-Saline group), some of the interactions
(any including Drug and Virus) were not calculated. Drug and Virus conditions included were
DREADD Nicotine (30 g/kg), Cre Nicotine, and DREADD Saline (0.9% sterile saline). Alpha
criterion was set at p0.05, significant interactions were investigated with second-orders
contrasts using Bonferroni’s correction for alpha inflation.
Experiment 2: Microdialysis
The % baseline was calculated for each sample and compared to 100% using a onesample t-test. The analysis was able to detect the difference in % baseline extracellular GABA
concentration after the first clozapine (0.75 mg/kg) and second clozapine (1.25 mg/kg) IP
injections.
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Results
Experiment 1
Acquisition. Responding significantly increased during acquisition, but only on the active
lever and only for rats that were self-administering nicotine. This was confirmed by a significant
Drug x Lever x Schedule interaction, F(3,18)= 7.893, p= 0.001. Second-order contrasts
confirmed that all groups showed greater active lever responding, relative to the inactive lever
(ps≤0.012) on the FR1 schedule as seen in Figure 1. However, during the FR2, FR5, and FR10
tests, this difference was observed in rats self-administering nicotine (ps<0.001) but not rats selfadministering saline (ps≥0.26). The difference between active and inactive levers in the Saline
group under the FR1 schedule was most likely driven by prior food shaping (e.g., only the active
lever was shaped). All animals were food shaped on an FR1 to promote lever pressing.

Figure 1: Active Lever Presses for Acquisition. Nicotine enhanced acquisition of the active lever
as FR increased. The DREADD Saline group decreased in active lever presses between FR1 and
FR2 represented by the pound sign (#). Asterisks (*) represent the significant increase in active
lever presses for nicotine as the FR increases.
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Treatment. An analysis of Virus x Levers x Tests between nicotine receiving groups
revealed a decrease in DREADD Nicotine lever presses with administration of clozapine
(0.75mg/kg) F(2,28) = 7.670, p = 0.002. The significance can be observed in Figure 2A on Test3
of clozapine between Cre and DREADD Nicotine F(1,14) = 8.195, p = 0.013. However, further
analysis of inactive lever presses also showed a significant decrease in DREADD Nicotine
(ps0.027) represented in Figure 2B. Overall, clozapine decreased active and inactive lever
responding in the DREADD Nicotine group. Lastly in reference to Figure 2A and 2B, clozapine
injections were replaced with 0.9% sterile saline. While the DREADD Nicotine group appeared
to gradually increase active lever responding, saline1 and saline2 showed a significant difference
in both active F(1,20) = 8.718, p = 0.008; F(1,20) = 4.481 p = 0.047, and inactive levers
(ps<0.001) when compared to Cre Nicotine.

Figure 2A: Active Lever Presses with Treatment. DREADD Nicotine decreased active lever
responding for nicotine in comparison to Cre Nicotine. Asterisks (*) represent the significant
difference between both groups. Active lever presses are also represented when clozapine was
replaced by saline.
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Figure 2B: Inactive Lever Presses with Treatment. A significance, denoted by Asterisks (*), can
be observed in inactive lever presses between Cre and DREADD Nicotine. Differences between
inactive responding can also be seen in regards to saline replacement.

Immunohistochemistry. The technique of immunohistochemistry (IHC) was performed to
ensure expression of the DREADD receptor and expression in correct anatomical location.
Perfused brain tissue was sliced at 20m and stained using a primary and secondary antibody.
The secondary antibody fluoresced the marker mCherry that was seen using a Olympus BX41
florescent microscope at the of wavelength 594 nm. The fluorescent mCherry indicated
DREADD expression in the NAc shown in Figure 3A. Expression was also present throughout
the entire neuron including cell body and projections represented in Figure 3B.
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Figure 3A: DREADD Localization. The fluorescent mCherry marker for DREADD expression
can be observed in the nucleus accumbens denoted NAc. Other anatomical landmarks are present
– anterior commissure (ac) and the lateral ventricle (LV) seen on 4x magnification.

4x

Figure 3B: DREADD Expression. Expression throughout the neuron indicated by the mCherry
marker.
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Experiment 2
Microdialysis was performed to confirm that the administration of clozapine activated the
DREADD receptor and caused an influx of GABA into the VP. Figure 4 shows that the first
injection of clozapine (0.75 mg/kg) (M=143.948, SD=29.08422) significantly increased the
concentration of GABA in the VP; t(4) = 3.379, p = 0.028. Lastly, no significance was found
with the second injection of clozapine (1.25 mg/kg), (p = 0.538).

Figure 4: Amount of GABA (%Baseline). The effects of the two different injections of clozapine
on % Baseline of GABA are shown. Asterisk (*) represent significance.
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Discussion
These experiments investigated the role of ventral striato-pallidal projections in nicotine
self-administration in rats using a chemogenetic strategy to increase GABA inhibition in the
indirect pathway of coritco-straito-thalamic circuits. To do so, a retrograde Cre-recombinase
virus was injected into the ventral pallidum (VP), followed several weeks later by injection of a
Cre-dependent DREADD receptor (hM3-DIO, cite) in the ventral striatum (nucleus accumbens,
or NAc). This strategy should allow injections of the designer drug (clozapine) to cause burst
firing of neurons projecting from the NAc to the VP, increasing GABA release, and activating
the indirect pathway. After we established reliable intravenous nicotine self-administration, we
found that clozapine administration increased GABA into the VP and caused a reduction in
active lever presses for nicotine. However, we also observed a decrease in inactive lever
responses, suggesting that the reduction of responding could have been a non-specific motor
deficit. During a recovery phase (saline injections substituted for clozapine), the DREADDNicotine group took two sessions for nicotine self-administration to return to control levels. Most
importantly, we found that the effects of clozapine were not based on off-target effects (e.g.,
dopamine D2 receptors) as a control group that did not receive DREADD receptors maintained
high rates of responding for nicotine. We also confirmed that the DREADD receptor was
expressed where we anticipated (NAc projection neurons) using IHC and that injection of
clozapine increased extracellular GABA in the VP using HPLC. Several of the findings deserve
further consideration, including the pattern of reduced nicotine self-administration and recovery
after clozapine injections, the putative non-specific motor effects of clozapine injection, and the
biochemical change in GABA observed in the microdialysis control experiment.
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Nicotine Self-Administration
We hypothesized that by increasing GABA into the VP, the reinforcing effects of
nicotine would decrease. Behavior consistent with the hypothesis was observed in active lever
presses related to clozapine administration. Surprisingly, responding declined gradually
suggesting that the activation of the DREADD receptor (e.g. increased GABA into the VP)
decreased the reinforcing effects of nicotine through extinction. ‘Extinction’ refers to a pattern of
operant responding that occurs when a reinforcer is removed – behavior gradually declines as the
subject learns a new contingency (that the response no longer leads to a reinforcer). Similar
experiments have increased GABA activity in the VP and revealed comparable results.
Muscimol, a GABAA agonist, was injected directly into the VP resulting in a decrease in cocaine
self-administration (Root et al. 2015). Also microinjections of neurotensin, a neuropeptide
thought to increase GABA, into the VP correspondingly decrease cocaine self-administration
(Torregrossa and Kalivas 2008). With the combined evidence of the current and previous studies,
an increase in GABA into the VP decreased non-specific drug self-administration. However,
further analysis of the current experiment depicted non-specific decrease in responding, as
inactive lever responses also decreased during testing.
The VP is a critical component of the indirect pathway of cortico-striato-thalamic
circuits. While any manipulation of striatal pathways could impact motor activity, the
consequences of increasing GABA in the VP during nicotine self-administration on motor
function has not been investigated. Our manipulation of increasing GABA by DREADD
activation could have induced mild locomotor deficits as evidenced by decreased inactive lever
responses. Inhibition of GABA receptors in the VP increases the initiation of activity in an openfield test (Mogenson & Nielsen 1983). In addition, GABA injections in the VP reduce
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hyperactivity caused by dopamine injections into the NAc (Mogenson & Nielsen 1983). Further
experiments investigating locomotor activity and GABA concentration within the VP will be
necessary to determine if the activation of the DREADD receptor decreased nicotine
reinforcement or caused inhibition of motor activity. However, another study used neurotensin, a
neuropeptide thought to increase GABA transmission by colocalizing with GABA release.
Neurotensin was placed in the NAc and caused an increase in GABA release in the VP,
extracellular GABA was measured with microdialysis. They found that the increase in GABA
did not have any effect on locomotor activity (Torregrossa and Kalivas 2008). The GABA
concentrations observed in our experiment were much lower when compared to the GABA
influx caused by neurotensin. Yet, we found a decrease in inactive lever presses. This could be a
result of the DREADD not being as specific as originally thought. The activation of D1 and D2like receptors may have had opposing effects.
Another interesting finding was how the active and inactive levers differed in reduced
responding with the administration of clozapine. Two days of clozapine injections were needed
to see an observable reduction in active lever presses (for nicotine infusions) of the DREADD
Nicotine group. Not until the third day was the group significantly different from Cre Nicotine in
active lever presses. Additionally, two days of saline were necessary for the DREADD Nicotine
to return to baseline nicotine responding. However, an immediate reduction in inactive lever
presses was observed in response to the first day of clozapine injections of both DREADD
Nicotine and Saline groups. Interestingly, the activity of inactive lever presses did not recover for
either group during the two day saline recovery. Interpretation of inactive lever behavior can
become complicated when considering that they may not be motivationally ‘neutral’. The
inactive lever could obtain low motivational value because of its association with the active
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lever. To further elaborate, with the DREADD Nicotine group, the inactive lever is physically
comparable to the active lever that resulted in nicotine delivery. Similarly, the active lever for the
DREADD Saline group historically resulted in sucrose delivery and is physically similar to the
inactive lever. Because the possible connection between the two levers, inactive lever presses
may not be an accurate measurement of spontaneous behavior when investigating motivation for
a reward. Therefore, it is possible that increasing GABA in the VP also reduces motivation for a
stimulus of low incentive value (inactive lever). Since this hypothesis is less parsimonious than
simply effecting motor activity, it should be tested in an open-field locomotor task as well.
Expression of the DREADD was confirmed at the anatomical location of interest (NAc)
with immunohistochemistry. Expression was observed in the both the core and shell of the NAc.
This pattern of expression is consistent with anatomical tracing data showing that the NAc core
and shell both send efferents to the VP. These subregions of the NAc both integrate in the direct
and indirect pathways. MSNs expressing DA D1-like receptors are thought to be localized within
the NAc core, while the MSNs expressing D2-like receptors are located in the shell (Root et al.
2015). DA has opposing effects on D1 and D2-like receptors and has been studied extensively
during drug self-administration. Other experiments have found that increasing D1 activity
(exciting the direct pathway) or antagonizing D2-like receptors (inhibiting the indirect pathway)
increases drug-seeking behaviors (Gallo et al. 2018). Nicotine is thought to alter the activity of
both resulting in habitual use (Benowitz 2010). No research has shown the effects of increasing
GABA using DREADD on D1 and D2-like receptor activity during nicotine self-administration.
Indeed, one reason for the slow-recruiting effect of clozapine in DREADD Nicotine rats may be
a lack of anatomical specificity. The DREADDs could have activated both direct and indirect
pathway projections from the accumbens. According to Kupchik and Kalivas (2016),
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differentiating the indirect and direct pathways based off D1 and D2-like receptors has been over
simplified and needs further investigation into more distinguishing factors. The gradual decrease
in nicotine self-administration observed in the presented data could have been a direct result of
DREADD activating both pathways. With that being said, we would need to negate the possible
counteractivity of nicotine and DREADD on the indirect and direct pathway.
Future Directions
To confirm DREADD expression and microdialysis probe placement, the tissue from
Experiment 2 will be sliced and stained. The implanted probe was injected with methylene blue
prior to tissue collection. The tissue will be sliced and the NAc will be stained for DREADD
expression while the methylene blue should be visible in the VP confirming correct probe
placement.
Locomotor testing will be completed to investigate the activity of DREADD induced
GABA release on the VP. The open field testing has been a reliable measure of locomotor
activity (Metz et al. 2000) and will be applied to measure the locomotor activity of rats
implanted with DREADD. Methods for viral implantation will be an exact replication of the
current study. Further investigation of increasing GABA into the VP on motor activity will
disclose if the observed decrease in inactive lever presses was overall decrease in motivation or
induced locomotor deficit.
Conclusion
The mesolimbic dopaminergic pathway is essential in substance abuse research. More
and more evidence has revealed the importance of certain nuclei, within the mesolimbic
pathway, in drug-associated behaviors. Investigating these projections has shown that the
motivational role of the NAc to VP pathway may be an important regulatory afferent from the
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mesolimbic system as part of the ‘indirect’ pathway. More recently this pathway has been
targeted by various manipulations resulting in the further understanding of its effects on drug
self-administration. This is the first time the NAc to VP pathway has been investigated for its
role in the reinforcing effects of nicotine with chemogenetic techniques. In conclusion, future
data combined with current will provide a clearer representation of the effects GABA in the VP
during drug-seeking behaviors.
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